Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
I was recently diagnosed with smoldering multiple myeloma. I have been told so far by two different myeloma specialist to just smolder. But one of them said I could go in their “early treatment” clinical trial that will be treating smm as mm for 2 years of clinical trial.
None of my test or imaging are showing any signs or symptoms except my monoclonal protein are high. My bone marrow biopsy showed 20% plasma cells in my bone marrow.
My Kappa light chain is 8%. I am 55yrs old African American woman.
Just researching from Dana Farber cancer institute. They believe you shouldn’t wait for your mm to become fully active to do something about it.
I am pretty healthy for the most part. I just went on high blood pressure medication about a month now. I am about to start a detoxification fast.
To help my body out some with certain kinds of nutritional things to help heal it as much as possible. I am interested in natural approaches to my health as much as I can. Anne
I would like to propose a different way to look at and treat your SMM. I will explain my thinking below.
I agree with Dana-Farber in that SMM patients shouldn’t wait for SMM to become full-blown MM. The challenge is that all of the clinical trials to date, have postponed progression yet all trials have documented side effects as well as leading to MM eventually. None of the clinical trail patients achieve a longer OS aka overall survival- length of life. I will link the studies below.
There are a host of evidence-based, non-toxic therapies that SMM patients can do/take that reduce the risk of full-blown MM yet don’t cause side effects. This is why I researched and created the pre-MM program.
I will link the nutrition guide below.
I apologize if I sound boring but there are a couple of issues you should consider before you undergo toxic therapies.
I have linked studies below that explain that your risk of progression is low (I think- I should study your diagnostic test info), the early treatment clinical trials result in harm and no positive outcomes and finally, a study explaining the benefits of pre-habilitating with non-toxic therapies.
I admit that reading studies and trying to decipher what they are saying is difficult.
I propose that I read your diagnostic testing info (SPEP, BMB, Complete blood count, metabolic panel, etc.) and apply the studies to your specific situation. In other words, I want to measure your risk of progression to a full-blown MM diagnosis and provide specific therapies shown to reduce your risk of MM.
Yes, in order to do the above, I will ask you to register for the pre-MM program and consultation with me. But there is a 30 day money back guarentee and I’m pretty sure that you will feel much more confident about your SMM diagnosis and therapy plan going forward.
And yes, during out consultation, if you choose to have one, I will explain antineoplaston therapy and the Burzynski Research Institute. And any/all questions you have about SMM, MM and other cancer questions you may have.
Let me know if you have any questions Ava.
Hang in there,
“SMM is distinct from monoclonal gammopathy of undetermined significance (MGUS) due to a higher risk of progression to active MM disease. For patients at high-risk of progressing from SMM, the main questions raised are; “should this subset of patients be treated as having MM?”.1…
Risk of progression from SMM to MM
Unlike MGUS which has a 1% risk of progression year on year, SMM carries a 15% risk within the first three years since diagnosis, which lowers to 3% between years three and 10, and drops to 1% at 10 years post-diagnosis.1 As SMM progresses into MM, there is an associated increase in M protein and BMPC percentage, as well as the development of end organ damage. Professor Kumar commented that this progression is a quantitative effect, over time. However, there are also qualitative genomic changes that occur over this time period within the plasma cells.
“We discuss evidence supporting early intervention for SMM—both as a preventative strategy to delay progression and as an intensive treatment strategy with a goal of potential cure. We highlight ongoing trials and focus on better defining who may require early intervention…”
Recently, the Eastern Cooperative Oncology Group revisited lenalidomide in SMM in a larger randomized study, E3A06. This study evaluated 182 patients with SMM and randomized patients to lenalidomide, as a single agent without dexamethasone (n = 90) vs. observation (n = 92) . Eligible patients had SMM with bone marrow plasma cells ≥10% and an abnormal sFLC ratio.
“Prehabilitation is not a new concept, nor is it specific to cancer. At its core, prehabilitation is designed to improve a person’s physical and psychological health in anticipation of an upcoming stressor. Furthermore, prehabilitation is part of the rehabilitation care continuum and is defined temporally as those assessments and interventions that occur after diagnosis but before acute treatment begins…
Many of the early studies on cancer prehabilitation typically focused exclusively on building strength and stamina through an appropriate exercise regimen; however, more recent research has supported a multimodal approach that encompasses more than one intervention (ie, a combination of exercise, nutrition, and psychological strategies) to better prepare patients for the challenges associated with upcoming cancer treatments.2…”